Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors
Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post‐vaccination antibodies. Thi...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13359 |
| _version_ | 1797856176146219008 |
|---|---|
| author | Eudald Felip Edwards Pradenas Margarita Romeo Silvia Marfil Benjamin Trinité Víctor Urrea Ainhoa Hernández Ester Ballana Marc Cucurull Lourdes Mateu Marta Massanella Bonaventura Clotet Teresa Morán Julià Blanco |
| author_facet | Eudald Felip Edwards Pradenas Margarita Romeo Silvia Marfil Benjamin Trinité Víctor Urrea Ainhoa Hernández Ester Ballana Marc Cucurull Lourdes Mateu Marta Massanella Bonaventura Clotet Teresa Morán Julià Blanco |
| author_sort | Eudald Felip |
| collection | DOAJ |
| description | Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post‐vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA‐1237 vaccine, and were compared with a group of 26 non‐cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS‐CoV‐2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non‐cancer groups were significant in individuals without previous SARS‐CoV‐2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non‐cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS‐CoV‐2 vaccination programs. |
| first_indexed | 2024-04-09T20:36:07Z |
| format | Article |
| id | doaj.art-cb23f6b2bc0042d091babfcdf72a34a2 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-04-09T20:36:07Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-cb23f6b2bc0042d091babfcdf72a34a22023-03-30T08:40:48ZengWileyMolecular Oncology1574-78911878-02612023-04-0117468669410.1002/1878-0261.13359Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumorsEudald Felip0Edwards Pradenas1Margarita Romeo2Silvia Marfil3Benjamin Trinité4Víctor Urrea5Ainhoa Hernández6Ester Ballana7Marc Cucurull8Lourdes Mateu9Marta Massanella10Bonaventura Clotet11Teresa Morán12Julià Blanco13IrsiCaixa AIDS Research Institute Badalona SpainIrsiCaixa AIDS Research Institute Badalona SpainMedical Oncology Department, Catalan Institute of Oncology – Badalona Badalona Applied Research Group in Oncology (B‐ARGO) SpainIrsiCaixa AIDS Research Institute Badalona SpainIrsiCaixa AIDS Research Institute Badalona SpainIrsiCaixa AIDS Research Institute Badalona SpainMedical Oncology Department, Catalan Institute of Oncology – Badalona Badalona Applied Research Group in Oncology (B‐ARGO) SpainIrsiCaixa AIDS Research Institute Badalona SpainMedical Oncology Department, Catalan Institute of Oncology – Badalona Badalona Applied Research Group in Oncology (B‐ARGO) SpainInfectious Diseases Department Hospital Universitari Germans Trias i Pujol Badalona SpainIrsiCaixa AIDS Research Institute Badalona SpainIrsiCaixa AIDS Research Institute Badalona SpainMedical Oncology Department, Catalan Institute of Oncology – Badalona Badalona Applied Research Group in Oncology (B‐ARGO) SpainIrsiCaixa AIDS Research Institute Badalona SpainPatients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post‐vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA‐1237 vaccine, and were compared with a group of 26 non‐cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS‐CoV‐2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non‐cancer groups were significant in individuals without previous SARS‐CoV‐2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non‐cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS‐CoV‐2 vaccination programs.https://doi.org/10.1002/1878-0261.13359adverse reactionsanticancer therapycancerCOVID‐19moderna vaccineneutralizing antibodies |
| spellingShingle | Eudald Felip Edwards Pradenas Margarita Romeo Silvia Marfil Benjamin Trinité Víctor Urrea Ainhoa Hernández Ester Ballana Marc Cucurull Lourdes Mateu Marta Massanella Bonaventura Clotet Teresa Morán Julià Blanco Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors Molecular Oncology adverse reactions anticancer therapy cancer COVID‐19 moderna vaccine neutralizing antibodies |
| title | Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors |
| title_full | Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors |
| title_fullStr | Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors |
| title_full_unstemmed | Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors |
| title_short | Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors |
| title_sort | impact of chemotherapy and or immunotherapy on neutralizing antibody response to sars cov 2 mrna 1237 vaccine in patients with solid tumors |
| topic | adverse reactions anticancer therapy cancer COVID‐19 moderna vaccine neutralizing antibodies |
| url | https://doi.org/10.1002/1878-0261.13359 |
| work_keys_str_mv | AT eudaldfelip impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT edwardspradenas impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT margaritaromeo impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT silviamarfil impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT benjamintrinite impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT victorurrea impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT ainhoahernandez impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT esterballana impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT marccucurull impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT lourdesmateu impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT martamassanella impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT bonaventuraclotet impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT teresamoran impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors AT juliablanco impactofchemotherapyandorimmunotherapyonneutralizingantibodyresponsetosarscov2mrna1237vaccineinpatientswithsolidtumors |